|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Dear Reader, welcome back to the StratCom news update. Sorry for the long absence. It was a very busy summer. Here are some of the highlights. Asuragen, Inc. a molecular biology service provider, entered into a co-exclusive license agreement with Garching Innovation, the technology transfer agency of the Max Planck Society. To obtain the rights to use over 200 microRNA sequences in diagnostic applications. AviaraDx entered into a research collaboration with the Massachusetts General Hospital Cancer Center to identify molecular profiles of multiple types of cancer for the development of diagnostic technologies and tests in the field of cancer drug response prediction. Celera Genomics, an Applera Corporation business, was awarded CE Mark for its RealTime HCV Genotype Assay. The company reported this is the first real-time test for genotyping the HCV virus to obtain regulatory approval for commercial sale in Europe. The test is designed for use on the automated ABI PRISM 7000 real-time PCR system from Applied Biosystems. The test was developed, and will be sold, through Celera's alliance with Abbott Diagnostics. Cepheid acquired Actigenics. Actigenics owns the therapeutic and diagnostic rights to validated microRNAs. Cepheid plans to develop proprietary markers for cancer, infectious diseases and inflammation. Cepheid may also develop diagnostic tests associated with therapeutic applications. Details of the purchase agreement were not disclosed. Ciphergen Biosystems and Bio-Rad Laboratories signed a definitive agreement for Bio-Rad to acquire Ciphergen's proprietary proteomics instrument business for approximately $20 million. The purchase includes Ciphergen's Surface Enhanced Laser Desorption/Ionization (SELDI) technology, ProteinChip Arrays and accompanying software. Bio-Rad will manufacture, sell and market the SELDI technology to the life sciences marketplace. Ciphergen will retain exclusive rights to the diagnostics market. Daiichi Pure Chemicals Co. Ltd, Toshiba Corporation, and Toshiba Hokuto Electronics Corporation have formed a collaboration to promote in-vitro DNA-chip-based diagnostics. The collaboration benefits from Toshiba's capabilities in DNA chips and electrochemical DNA detection and analysis, and Daiichi Pure Chemicals' in-vitro diagnostic knowledge. The first application is for HPV testing. Epigenomics AG has acquired assay technologies from Affymetrix and Qiagen to be used in the development of DNA methylation-based microarrays. The first products based on this platform will be pathology tests in prostate and breast cancer. Epigenomics is planning to transfer its Molecular Classification Test for prostate cancer onto the Affymetrix platform to use it in the pivotal clinical trial for FDA approval of the assay, which is scheduled to start in 2007. Illumina and deCODE Genetics formed an alliance to develop DNA diagnostics for the risk of heart attack, type 2 diabetes, and breast cancer. Illumina will gain access to disease-related biomarkers for joint validation as diagnostic panels to be marketed and sold by Illumina on its forthcoming BeadXpress platform. The companies will share development costs and split the profits from sales of the diagnostics tests. OpGen Technologies is developing optical mapping instruments and disposables for research and clinical microbiology applications. The optical mapping system is designed to investigate changes in genome structure in organisms that have not yet been sequenced. The company expects to launch the first system early in 2007.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: October 25, 2006 |
![[Page Banner Image]](images/hmole.gif){kind=small}
